Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice
- 17 March 2009
- journal article
- research article
- Published by Elsevier BV in Behavioural Brain Research
- Vol. 198 (2), 434-439
- https://doi.org/10.1016/j.bbr.2008.11.027
Abstract
No abstract availableThis publication has 69 references indexed in Scilit:
- Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit HypothesisCell Transplantation, 2006
- Gait dynamics in mouse models of Parkinson's disease and Huntington's diseaseJournal of NeuroEngineering and Rehabilitation, 2005
- Toxin-induced models of Parkinson’s diseaseNeuroRX, 2005
- Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanismProgress in Neurobiology, 2005
- Differential expression of cytokines in the brain and serum during endotoxin toleranceJournal of Neuroimmunology, 2005
- Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogenJournal of Neural Transmission, 2003
- Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 2003
- Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long term losses of dopamine neurons in offspring a potential new model of parkinson s diseaseFrontiers in Bioscience-Landmark, 2003
- Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic SystemJournal of Neurochemistry, 1998
- Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonismBrain Research, 1990